Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Accumulated Expenses (2016 - 2025)

China Pharma Holdings filings provide 16 years of Accumulated Expenses readings, the most recent being $350643.0 for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 41.87% to $350643.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $350643.0, a 41.87% increase, with the full-year FY2025 number at $350643.0, up 41.87% from a year prior.
  • Accumulated Expenses hit $350643.0 in Q4 2025 for China Pharma Holdings, up from $170426.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $1.3 million in Q3 2024 to a low of $110387.0 in Q2 2022.
  • Median Accumulated Expenses over the past 5 years was $198550.0 (2021), compared with a mean of $261330.0.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 949.15% in 2024 and later tumbled 86.43% in 2025.
  • China Pharma Holdings' Accumulated Expenses stood at $298452.0 in 2021, then surged by 35.64% to $404807.0 in 2022, then decreased by 26.18% to $298829.0 in 2023, then dropped by 17.29% to $247159.0 in 2024, then surged by 41.87% to $350643.0 in 2025.
  • The last three reported values for Accumulated Expenses were $350643.0 (Q4 2025), $170426.0 (Q3 2025), and $191293.0 (Q2 2025) per Business Quant data.